IBRX
Income statement / Annual
Last year (2024), ImmunityBio, Inc.'s total revenue was $14.75 M,
an increase of 2,270.58% from the previous year.
In 2024, ImmunityBio, Inc.'s net income was -$413.56 M.
See ImmunityBio, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$14.75 M |
$622.00 K |
$240.00 K |
$934.00 K |
$605.00 K |
$43.00 K |
$47.00 K |
$45.00 K |
$44.00 K |
$236.00 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.01 M
|
-$3.11 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$14.75 M
|
$622.00 K
|
$240.00 K
|
$934.00 K
|
$605.00 K
|
-$8.97 M
|
$3.16 M
|
$45.00 K
|
$44.00 K
|
$236.00 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
-208.58
|
67.17
|
1
|
1
|
1
|
| Research and Development Expenses |
$190.14 M
|
$232.37 M
|
$248.15 M
|
$195.96 M
|
$139.51 M
|
$48.89 M
|
$53.42 M
|
$39.78 M
|
$26.55 M
|
$11.43 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$28.39 M
|
$57.12 M
|
$95.39 M
|
$227.68 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.07 M
|
-$3.30 M
|
-$1.00 M
|
-$1.47 M
|
| Selling, General & Administrative Expenses |
$168.78 M
|
$129.62 M
|
$102.71 M
|
$135.26 M
|
$71.32 M
|
$9.05 M
|
$35.46 M
|
$53.82 M
|
$94.39 M
|
$226.21 M
|
| Other Expenses |
$0.00
|
$886.00 K
|
$681.00 K
|
$0.00
|
$10.66 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$358.93 M
|
$362.87 M
|
$351.54 M
|
$331.21 M
|
$221.49 M
|
$57.94 M
|
$88.88 M
|
$93.60 M
|
$120.94 M
|
$237.64 M
|
| Cost And Expenses |
$358.93 M
|
$362.87 M
|
$351.54 M
|
$331.21 M
|
$221.49 M
|
$66.95 M
|
$98.44 M
|
$99.17 M
|
$124.54 M
|
$239.11 M
|
| Interest Income |
$2.40 M
|
$863.00 K
|
$2.71 M
|
$836.00 K
|
$1.73 M
|
$2.76 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$131.66 M
|
$86.72 M
|
$47.15 M
|
$14.85 M
|
$9.07 M
|
$5.92 M
|
$433.00 K
|
$618.00 K
|
$66.00 K
|
$0.00
|
| Depreciation & Amortization |
$17.55 M
|
$18.51 M
|
$18.26 M
|
$14.24 M
|
$12.74 M
|
$9.01 M
|
$9.56 M
|
$5.57 M
|
$3.61 M
|
$1.47 M
|
| EBITDA |
-$264.43 M |
-$478.66 M |
-$351.88 M |
-$320.75 M |
-$204.22 M |
-$56.86 M |
-$86.74 M |
-$90.73 M |
-$117.71 M |
-$235.71 M |
| EBITDA Ratio |
-17.93
|
-769.55
|
-1466.17
|
-343.42
|
-337.55
|
-1322.21
|
-1845.55
|
-2016.27
|
-2675.18
|
-998.75
|
| Operating Income Ratio |
-23.34
|
-582.4
|
-1463.74
|
-353.62
|
-365.09
|
-1555.98
|
-2093.38
|
-2202.67
|
-2829.55
|
-1012.19
|
| Total Other Income/Expenses Net |
-$69.46 M
|
-$221.64 M
|
-$65.99 M
|
-$19.56 M
|
-$5.15 M
|
$1.02 M
|
$1.66 M
|
$2.20 M
|
$3.12 M
|
$1.70 M
|
| Income Before Tax |
-$413.65 M
|
-$583.89 M
|
-$417.29 M
|
-$349.84 M
|
-$226.03 M
|
-$65.89 M
|
-$96.73 M
|
-$96.92 M
|
-$121.38 M
|
-$237.18 M
|
| Income Before Tax Ratio |
-28.05
|
-938.73
|
-1738.69
|
-374.56
|
-373.61
|
-1532.23
|
-2058.06
|
-2153.69
|
-2758.66
|
-1004.99
|
| Income Tax Expense |
$0.00
|
-$40.00 K
|
$34.00 K
|
$9.00 K
|
-$1.85 M
|
-$97.00 K
|
-$503.00 K
|
-$493.00 K
|
-$572.00 K
|
-$301.00 K
|
| Net Income |
-$413.56 M
|
-$583.20 M
|
-$416.57 M
|
-$346.79 M
|
-$221.85 M
|
-$65.79 M
|
-$96.23 M
|
-$96.42 M
|
-$120.81 M
|
-$236.88 M
|
| Net Income Ratio |
-28.05
|
-937.61
|
-1735.7
|
-371.3
|
-366.7
|
-1529.98
|
-2047.36
|
-2142.73
|
-2745.66
|
-1003.71
|
| EPS |
-0.59 |
-1.15 |
-1.04 |
-0.89 |
-0.59 |
-0.42 |
-0.3 |
-0.3 |
-0.37 |
-0.73 |
| EPS Diluted |
-0.62 |
-1.15 |
-1.04 |
-0.89 |
-0.59 |
-0.42 |
-0.3 |
-0.3 |
-0.37 |
-0.73 |
| Weighted Average Shares Out |
$697.31 M
|
$508.64 M
|
$399.90 M
|
$389.23 M
|
$383.18 M
|
$383.18 M
|
$325.05 M
|
$316.15 M
|
$328.55 M
|
$326.30 M
|
| Weighted Average Shares Out Diluted |
$700.44 M
|
$508.64 M
|
$399.90 M
|
$389.23 M
|
$383.18 M
|
$383.18 M
|
$325.05 M
|
$316.15 M
|
$328.55 M
|
$326.30 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
